UCB SA (EBR:UCB)
225.80
+0.70 (0.31%)
Aug 11, 2026, 12:57 PM CET
UCB SA Revenue
UCB SA had revenue of 4.27B EUR in the half year ending June 30, 2026, with 52.99% growth. This brings the company's revenue in the last twelve months to 8.52B, up 24.47% year-over-year. In the year 2025, UCB SA had annual revenue of 7.74B with 25.83% growth.
Revenue (ttm)
8.52B
Revenue Growth
+24.47%
P/S Ratio
5.03
Revenue / Employee
947.11K
Employees
9,000
Market Cap
42.92B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 7.74B | 1.59B | 25.83% |
| Dec 31, 2024 | 6.15B | 900.00M | 17.14% |
| Dec 31, 2023 | 5.25B | -265.00M | -4.80% |
| Dec 31, 2022 | 5.52B | -260.00M | -4.50% |
| Dec 31, 2021 | 5.78B | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | - | - | - |
| Dec 31, 2018 | 4.63B | 102.00M | 2.25% |
| Dec 31, 2017 | 4.53B | 383.00M | 9.24% |
| Dec 31, 2016 | 4.15B | 271.00M | 6.99% |
| Dec 31, 2015 | 3.88B | 532.00M | 15.91% |
| Dec 31, 2014 | 3.34B | 211.00M | 6.73% |
| Dec 31, 2013 | 3.13B | -329.00M | -9.50% |
| Dec 31, 2012 | 3.46B | 216.00M | 6.65% |
| Dec 31, 2011 | 3.25B | 28.00M | 0.87% |
| Dec 31, 2010 | 3.22B | 102.00M | 3.27% |
| Dec 31, 2009 | 3.12B | -485.00M | -13.47% |
| Dec 31, 2008 | 3.60B | -25.00M | -0.69% |
| Dec 31, 2007 | 3.63B | 1.08B | 42.14% |
| Dec 31, 2006 | 2.55B | 210.00M | 8.97% |
| Dec 31, 2005 | 2.34B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| argenx SE | 4.65B |
| European Medical Solutions | 52.80M |
| Hyloris Pharmaceuticals | 7.94M |
| Onward Medical | 5.41M |
| Oxurion NV | 555.00K |
| Celyad Oncology | 21.00K |
| Financière de Tubize | 13.26K |
| BioSenic | -2.39M |
UCB SA News
- 8 days ago - UCB upgraded to Hold from Underperform at Jefferies - TheFly
- 11 days ago - UCB SA Earnings Call Transcript: H1 2026 - Transcripts
- 11 days ago - UCB SA Earnings release: H1 2026 - Filings
- 11 days ago - UCB SA Quarterly report: H1 2026 - Filings
- 11 days ago - UCB SA Slides: H1 2026 - Filings
- 12 days ago - UCB shares fall despite guidance upgrade as investors question earnings quality - Reuters
- 19 days ago - UCB Maintained by DA Davidson -- Price Target Stays at $40 - GuruFocus
- 20 days ago - UCB (UCB) Q2 2026 Earnings Call Transcript - The Motley Fool